A Phase 2 interventional study of Collagenase Clostridium Histolyticum (CCH) and Placebo in Plantar Fasciitis, sponsored by Endo USA Inc., a Keenova Therapeutics Company. Completed at 39 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-30.
Sponsored by Endo USA Inc., a Keenova Therapeutics Company (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Fasciitis, Plantar with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Fasciitis, Plantar · United States.
Among the 45 studies in Fasciitis, Plantar with a site in United States, this one is the 2nd largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 2, and was the 40th registered.
223 studies on the registry are indexed under Fasciitis, Plantar; 58 are open to participants now.
Browse Fasciitis, Plantar studies →6 of the 45 studies in Fasciitis, Plantar with a site in United States are open now. Recruiting first, the newest first:
SAE Orthopedics · Sites in United States
Ages 18+
Joint & Vascular Institute · Sites in United States
Ages 25–80
IR Centers · Sites in United States
Ages 22–100
University of Florida · Sites in United States
Ages 18–100 · Healthy volunteers
University of South Florida · Sites in United States
Ages 50–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 29 Fasciitis, Plantar studies recruiting now, 5 (17%) set no upper age limit and 21 (72%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 4 · Phase 4 4
First in 2005; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 231 is above the median of 56 across 194 interventional studies indexed under Fasciitis, Plantar.
Median enrollment 55 across the 44 interventional studies, 43 across the 1 observational. Of the 32 that completed or were terminated, 10 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Endo USA Inc., a Keenova Therapeutics Company, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo USA Inc., a Keenova Therapeutics Company is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Keenova Therapeutics plc has 1 study filed under Fasciitis, Plantar — fewer than ten, so there is no comparison to draw.
3 of the studies in Fasciitis, Plantar with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05075005University of FloridaThe Effects of Terrain Variation on Intrinsic Foot Musculature in Healthy Individuals and Individuals With Plantar Fasciitis | 2027-01-20 |
| NCT07395128Joint & Vascular InstituteLateral Plantar Artery Embolization For Plantar Fasciitis | 2027-03 |
| NCT07776405University of FloridaA Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 45 studies in Fasciitis, Plantar with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a high dose of CCH on Day 1.
Biological: Collagenase Clostridium Histolyticum (CCH)
Participants will receive a low dose of CCH on Day 1.
Biological: Collagenase Clostridium Histolyticum (CCH)
Participants will receive matching placebo on Day 1.
Biological: Placebo
Biologic: Intrafascial injection
Also known as: EN3835
Intrafascial injection
Change from Baseline at Week 12 in the Weekly Mean of the Average Daily (24-hour) Pain (ADP) Score as Measured on the Pain Intensity Numeric Rating Scale (NRS)
Time frame: Baseline, Week 12
Change from Baseline up to Day 85 in the Foot Function Index (FFI) Difficulty Subscale Score
Time frame: Baseline, up to Day 85
Change from Baseline up to Day 85 in the FFI Activity Limitation Subscale Score
Time frame: Baseline, up to Day 85
Change from Baseline up to Week 12 in the Weekly Mean of the ADP Score as Measured on the Pain Intensity NRS
Time frame: Baseline, up to Week 12
Change from Baseline up to Day 85 in the FFI Pain Subscale Score
Time frame: Baseline, up to Day 85
Change from Baseline up to Day 85 in the FFI Total Score
Time frame: Baseline, up to Day 85
Number of Participants That Used Rescue Analgesic Medication
Time frame: Up to Day 85
Total Amount (milligrams [mg]) of Rescue Analgesic Medication Used
Time frame: Up to Day 85
Patient Global Impression of Change (PGIC) Foot Pain Scale Score
Time frame: Up to Day 85
Clinician Global Impression of Change (CGIC) Scale Score
Time frame: Up to Day 85
Subject Satisfaction with Treatment Scale Score
Time frame: Up to Day 85
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in Sep 2024, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase
Endo USA Inc., a Keenova Therapeutics Company →